The Gastrointestinal Cancer Channel is supported with funding from Gilead Sciences (Silver) and Revolution Medicines (Silver).
VJOncology is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASCO GI 2023 | Claudin 18.2 as an emerging target in gastrointestinal cancers
David Bing Zhen, MD, University of Washington Medicine, Seattle, WA, describes the rationale behind targeting claudin 18.2 in gastrointestinal cancers. Claudin 18.2 is a tight-junction protein that is highly expressed in cancers, and has subsequently become a promising target. Dr Zhen highlights multiple monoclonal antibodies and cellular immunotherapies in development that may especially benefit pre-treated patients. This interview took place at the American Society of Clinical Oncology (ASCO) 2023 Gastrointestinal Cancers (GI) Symposium in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
